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ABSTRACT
Background. Breast cancer brain metastasis (BCBM) confers a
poorprognosis and is unusual in requiringmultidisciplinarycare
in the metastatic setting. The University of North Carolina at
Chapel Hill (UNC-CH) has created a BCBM clinic to provide
medical and radiation oncology, neurosurgical, and supportive
services to this complex patient population. We describe
organization and design of the clinic as well as characteristics,
treatments,andoutcomesofthepatientsseenin its first3years.
Methods. Clinical and demographic data were collected from
patients in a prospectively maintained database. Descriptive
statistics are reported as percentages andmeans. The Kaplan-
Meier method was used to estimate time-to-event outcomes.
Results. Sixty-five patients were seen between January 2012
and January 2015. At the time of presentation to the BCBM
clinic, most patients (74%) had multiple ($2) brain metasta-
ses and had received prior systemic (77%) and whole-brain
radiation therapy and/or central nervous system stereotactic
radiosurgery (65%) in the metastatic setting. Seventy-eight
percent returned for a follow-up visit; 32% were enrolled in a
clinical trial.Median time fromdiagnosis of brainmetastasis to
death was 2.11 years (95% confidence interval [CI] 1.31–2.47)
for all patients, 1.15 years (95%CI 0.4–2.43) for triple-negative
breast cancer, 1.31 years (95% CI 0.51–2.52) for hormone
receptor-positive/HER22 breast cancer, and 3.03 years (95%
CI lower limit1.94,upper limitnotestimable) forHER21breast
cancer (p5 .0037).
Conclusion. Patients with BCBM have unique and complex
needsthat require input fromseveraloncologicdisciplines.The
development of the UNC-CHmultidisciplinary BCBM clinic is a
model that can be adapted at other centers to provide
coordinated care for patients with a challenging and complex
disease. The Oncologist 2016;21:16–20
Implications for Practice: Patients with breast cancer brain metastases often require unique multidisciplinary care to meet the
numerous and uncommon challenges associated with their conditions. Here, the development and characteristics of a clinic
designed specifically to provide for themultidisciplinary needs of patients with breast cancer brainmetastases are described.This
clinic may serve as a model for other institutions interested in creating specialty clinics with similar objectives.
INTRODUCTION
Approximately 15% of women with newly diagnosed meta-
static breast cancer will develop metastases to the brain [1];
however, autopsy studies show that the incidence may be
as high as 30% [2]. Although all patients with breast cancer
are at risk for central nervous system (CNS) recurrence, those
with advanced human epidermal growth receptor 2-positive
(HER21) and triple-negative breast cancer are at highest risk,
with approximately 30% and 50% developing brain metas-
tases, respectively [3, 4].
Survival from the diagnosis of breast cancer brain metas-
tasis (BCBM) varies by study, but historically ranges from 2 to
16 months [2, 5]. Survival after brain recurrence depends on
many factors, including the extent of extracranial disease,
performance status, and receipt of local or systemic therapy
[5, 6]. Moreover, retrospective studies have illustrated profound
differences in survival after a diagnosis of brain metastases
arising from breast cancer by receptor status: approximately
15months for luminal subtype, up to 12–18months for HER21,
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and only 4 months for triple-negative breast cancer [7–10]. Dif-
ferences in outcome for patients with breast cancer brain
metastases based on these many factors highlight the need for a
tailored approach and coordinated care of this patient population.
At present, local therapy remains the mainstay for the
majority of patients with brain metastases arising from
breast cancer. Neurosurgical resection is generally reserved
for situations in which the diagnosis is uncertain or there is a
solitary, large, or symptomatic lesion in the brain [11]. Whole-
brain radiation therapy (WBRT), typically reserved for patients
with multiple brain metastases, has shown documented re-
sponse in more than 60% of patients in randomized controlled
studies [12]. Survival after WBRT is highly dependent on
performancestatus,controlofextracranialdisease,breastcancer
subtype, and patient age [13, 14]. Stereotactic radiation surgery
(SRS) is generally reserved for fewer intracranial lesions (#3) of
smaller size, generally ,3 cm [15]. Central nervous system
recurrence rate after SRS in the salvage setting is approximately
6months,andoverall survival is10months[16].Moreover,SRScan
be recommended alone orwithWBRT. Although neurocognitive
decline is less apparent after SRS comparedwith SRS plusWBRT,
intracranial recurrence rates are higher andmore frequent [17].
Receiptofsystemicendocrinetherapy,chemotherapy,orbiologic
therapy prolongs survival in patients with hormone receptor-
positive (HR1) and HER21 breast cancer brain metastases [7].
Given the need for careful sequencing of therapeutic options
as well as prompt decision-making in complex health care
situations, open communication between neurosurgery, medi-
cal, and radiation oncology is essential to develop the most
efficient and effective plan of care for patients with BCBM.
We have designed and implemented a weekly multidisci-
plinary BCBMclinic at theUniversityofNorthCarolina at Chapel
Hill (UNC-CH) and Lineberger Comprehensive Cancer Center.
Ourgoal isto improveoutcome,enhancequalityof life,andoffer
novel and coordinated therapeutic strategies for patients with
BCBM.Toourknowledge,this is the first clinicof its kinddevoted
specifically to the multidisciplinary care of patients with breast
cancerbrainmetastases.Herein,wedescribe the logisticsof this
unique clinic, patient demographics and clinical characteristics,
and treatment approaches for patients seen during the first 36
months of the clinic’s operation as amechanism to disseminate
our experiences to the broader oncology community, with the
goal of fostering the development of similar clinics at cancer
centers both within and outside of the United States.
MATERIALS AND METHODS
Clinic Organization
TheUniversity of North Carolina Chapel Hill Breast Cancer Brain
Metastases Clinic was established on January 1, 2012. It is a
weekly multidisciplinary clinic designed to meet the needs of
patients with central nervous system metastases from breast
cancer. Patients are often referred to us by their primary
oncologist within or outside of the UNC system. During their
initial visit to the clinic, patients are seen by radiation oncology,
medicaloncology,andneurosurgery (as indicated),andan initial
treatment plan is recommended. Patients are offered avail-
able clinical trials, both local and systemic, as appropriate. The
need for evaluation by additional supportive services such as
palliative care, physical therapy, psychiatry, or nutrition is
assessed, and referrals or same-day consultations are arranged
as necessary. Team members include a medical oncologist
specializing in breast oncology, a radiation oncologist, a
neurosurgeon, a nurse practitioner, and a nurse navigator.
Recent imaging studies, including brain magnetic resonance
imaging (MRI) and or computed tomography, are reviewed by
team members before and during each appointment. Some
patients are seen for a one-time consultation; however, some
patients return to the clinic for continued care with medical
oncology, radiation oncology, or neurosurgery. If patients are
managed by an outsidemedical oncologist, they return to their
localmedical oncologist tocarryout recommended treatments.
If recommended therapies are not available closer to home
(i.e., in a clinical trial only), patients will have the option to
transition their ongoing care during a clinical trial, for instance,
to their UNC brain metastases clinic provider. Once the trial
activities are complete, they have the option to return to their
local medical oncologist. Patients then typically return to UNC
for routine brain MRI screening every 12 weeks for continued
recommendationsbasedon their routine surveillance scans. If a
patient has a UNC provider, the brain metastases consulting
medical oncologist is frequently asked tomeet with patients at
timeofprogressionorforclinical trial screening.Aswithpatients
fromoutsidetheUNCsystem,patientsareabletoreturn totheir
UNC provider, even if on a clinical trial, as our providers are all
listed as coinvestigators on the BCBM clinical trials.
Data Collection
A protocol was designed and approved by the institutional
review board to retrospectively collect and analyze basic
demographic data and clinical information of patients seen at
the UNC-CH Breast Cancer Brain Metastases Clinic. Patients
were identified through query of the UNC Breast Cancer
Metastatic Database, a prospectively maintained internal
RedCap clinical database containing information pertaining to
clinical factors and outcomes of metastatic breast cancer
patients seen at the UNC Cancer Hospital. All information
within the database was manually extracted from UNC’s
electronic medical records (EPIC). Additional information was
obtained from Mosaiq, the radiation oncology intake system
used at UNC, and WebCis, an older electronic medical record
previously used at UNC. The following information was obtained
for all new patients seen in this clinic during the specified time
period: interval between first clinic date and first treatment,
informationon referral date and returnappointments, numberof
brain metastases, immunohistochemistry subtype (based on tis-
sue available from craniotomy, primary breast resection, or any
non-CNS metastatic site), stage at diagnosis, enrollment in clinical
trials, time fromdiagnosis of breast cancer to brainmetastases,
and time from brain metastases to death. Survival status was
primarily obtained from electronic medical records, but if a
patientwas no longer regularly seen atUNC, survival statuswas
obtained from obituaries as well as reports from the social
security death index and North Carolina Vital Statistics.
Statistical Analysis
Patients were classified into subtypes based on immunohisto-
chemistry testing of brain tissue when available (n5 13) or by
primary tumor (n5 52). Clinical breast cancer was subdivided
into three categories by status of HR (estrogen receptor [ER],
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progesterone receptor [PR], or both) and HER2: HR1/HER22,
HR1/HER21, and ER2, PR2, and HER22 (triple-negative
breast cancer [TNBC]). Descriptive statistics are reported as
percentages and means.The Kaplan-Meier method was used to
estimate time-to-event outcomes, with median times reported.
RESULTS
Sixty-fivepatientswithbreast cancerandbrainmetastaseswere
seen in the UNC Breast Cancer Brain Metastases Clinic from
January 1, 2012, to January 1, 2015. Baseline clinical character-
istics at the time of presentation are summarized in Table 1. In
brief, all patients were female, and average age at first clinic
appointmentwas52.8years.Themajorityof referralswere from
within North Carolina (83%), but patients from South Carolina,
Tennessee, and Virginia were also seen. More than half of the
patients were stage III or IV at initial breast cancer diagnosis.
Breast cancer receptor status was as follows: 37% HR1, 38%
HER21, and 25% TNBC; 83% had extracranial disease. A
significant proportionofpatients (92%) received chemotherapy
for treatment of early-stage breast cancer (premetastatic), and
the majority (77%) in the metastatic setting (40% had$2 lines
of chemotherapy in the metastatic setting). Prior adjuvant
treatment with endocrine therapy (41%) and HER2-directed
therapy (31%)wasobserved in a significantminorityofpatients;
68% of patients received at least one of these treatments in the
metastatic setting. Nearly two thirds (65%) of patients had
receivedCNS radiationbefore entering the clinic (26 of 65 [40%]
receivedWBRTonly,10of65[15%]receivedSRSonly,and6of65
[9%]receivedbothWBRTandSRS).Withregardtoneurosurgery,
22% had undergone a prior craniotomy. The majority (74%) had
multiple ($2) brain metastases on presentation to the clinic.
The average time from request for a consult to first
appointment was 4.5 days (median 2 days); 89% of patients
were seen within 1 week. Seventy-eight percent of patients
returned for a follow-up visit, and 32% of clinic patients re-
ceived an investigational systemic therapy through a clinical
trial. Twenty-five patients went on to receive CNS radiation
treatment during the time period examined: 8 of 25 (32%)
WBRT, 15 of 25 (60%) SRS, and 2 of 25 (8%) both. Seven (11%)
patients underwent craniotomy after consultation at the
BCBM clinic during the time period examined. Of these 7
patients, 5 (71%) had SRS and 2 (29%) had no additional
radiation (none had WBRT or SRS plus WBRT). Almost all
patients received systemic therapy recommendations at the
initial visit, and 35 clinic patients received systemic therapy at
UNCafter their clinic consult: 31 (89%) receivedchemotherapy
and 22 (63%) received hormone- or HER2-targeted therapy.
Median follow-up for patients in this cohortwas 10.3months.
At the timeof this analysis, 37 patients had died.Themedian time
from diagnosis of primary breast cancer to diagnosis of brain
metastaseswas3.11years(95%confidenceinterval[CI]2.22–3.88)
for all patients, 2.91 years (95%CI 1.19–3.46) for TNBC, 5.57 years
(95% CI 2.26–8.67) for HR1/HER22, and 1.67 years (95% CI
1.23–5.1) forHER21 (p5 .0025).Themedian time fromdiagnosis
ofbrainmetastases todeathwas2.11years (95%CI1.31–2.47) for
allpatients,1.15years (95%CI0.4–2.43) forTNBC,1.31years (95%
CI 0.51–2.52) for HR1/HER22, and 3.03 years (95%CI lower limit
1.94,upper limitnotestimable) forHER21 (p5 .0037) (Fig.1).The
median time from first clinic visit to death was 1 year (95%
CI0.70–1.85)forallpatients,0.38years(95%CI0.3–0.72)forTNBC,
0.89 years (95% CI 0.49–1.95) for HR1/HER22, and 1.85 years
(95% CI 0.93 to not estimable) for HER21 (p5 .0016).
DISCUSSION
The mission of the UNC-CH Breast Cancer Brain Metastases
Clinic is to improve outcomes, enhance quality of life, and offer
new therapeutic strategies for patients with BCBM.We report
onthefirst36monthsofourclinic,duringwhichtime65patients
with BCBM were seen, evaluated, and treated in this unique
clinic. The patient population was heterogeneous, comprising
patients with newly diagnosed and untreated brainmetastases
as well as patients previously treated elsewhere.Most patients
seen in the clinic received systemic therapy recommendations
Table 1. Demographic and clinical characteristics of patients
(n5 65) at presentation to the multidisciplinary BCBM clinic
Characteristic Value
Female 65 (100)
Average age at first clinic appointment, years 52.8
State of residence
North Carolina 54 (83)
South Carolina 4 (6)
Virginia 6 (9)
Tennessee 1 (2)
Presence of multiple brain metastases 48 (74)
Presence of extracranial disease 54 (83)
Histologic subtype
HR1/HER22 24 (37)
HER21 25 (38)
TNBC 16 (25)
Stage at diagnosis
Ductal carcinoma in situ 3 (5)
I 4 (6)
II 11 (17)
III 21 (32)
IV 18 (28)
Unknown 8 (12)
Treatment for early-stage breast cancer (n5 39)
Chemotherapy 36 (92)
Endocrine therapy 16 (41)
HER2-directed therapy 12 (31)
Prior treatment in the metastatic setting
Lines of chemotherapy [median (range)] 1 (0–8)
Chemotherapy (1 line) 24 (37)
Chemotherapy ($2 lines) 26 (40)
Endocrine or HER2-directed therapy 44 (68)
CNS radiation 42 (65)
WBRTonly 26 (40)
SRS only 10 (15)
WBRT and SRS 6 (9)
Craniotomy 14 (22)
Data are presented as n (%) unless noted otherwise.
Abbreviations: BCBM, breast cancer brainmetastasis; CNS, central nervous
system; SRS, stereotactic radiation surgery; TNBC, triple-negative breast
cancer; WBRT, whole-brain radiation therapy.
©AlphaMed Press 2016
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fromabreastmedicaloncologistwithparticularexperiencetreating
brainmetastases;more than half of patients received that systemic
therapy at UNC, often on a clinical trial. More than a third of
patients received radiation therapy through a radiation oncology
team specializing in treatment of patients with CNS metastases.
Those who required neurosurgical intervention had timely access
to appropriate care, whether the intervention was performed
after their initial visit or later in their disease course.Most patients
returned for follow-up care, and one third were enrolled in avail-
able clinical trials appropriate for patients with CNSmetastases.
To our knowledge, the UNC-CH Breast Cancer Brain
Metastases Clinic is the first specialty clinic dedicated to the
care of patients with brain metastases exclusively from breast
cancer. A 2010 article published in Supportive Care in Cancer [18]
described a pilot brain metastases clinic that was established in
Alberta, Canada. It reported factors such as referral patterns,
time from referral date to clinic date, basic demographic and
clinical data of the patients, performance status, what services
thepatientsrequiredandused,andresultsofpatientsatisfaction
surveys. Multiple tumor types were included in the report, but
patients with lung cancer represented the majority of patients
[18]. Given that patients with breast cancer brain metastases
represent adistinct populationwithdifferentneeds frompatients
with non-CNS metastatic breast cancer, and whose prognosis
differs frompatientswithbrainmetastasesofotherprimary types,
we believe the development of our clinic and the subsequent
report of our first 3 years of experience illustrate the feasibility of
effectively addressing the needs ofmany patients with BCBM in a
specialized, multidisciplinary setting. Moreover, and given the
rapidrateofclinicaldeclinewhentheyare leftuntreated,wefeel
that it is imperative that patients with BCBM be seen as
expeditiously as possible and receive coordinated care during
what can often be a narrowwindow of clinical stability.
One of the strengths of a dedicated BCBM clinic is the ability
to offer unique opportunities for patients through clinical trial
participation in relevant areas such as drug development, novel
radiation techniques, neuroimaging, cancer genomics, and quality
of life studies.Forexample,thecurrentclinical trialportfolioatUNC
includes several therapeutic clinical trials evaluating novel drug
combinations and/or novel therapeutic delivery platforms for
patients with breast cancer brain metastases (ClinicalTrials.gov
identifiers NCT01305941 and NCT02048059), novel imaging tech-
niques to evaluate radiation necrosis/pseudoprogression versus
true tumor progression using positron emission tomography/
MRI techniques, and behavioral studies including evaluation of
neurocognitive outcomes after whole-brain radiation therapy in
patients with newly diagnosed BCBM. Furthermore, tissue-based
correlative studies are particularly important in this population.
Studying the kinetics of anticancer therapy in CNS is difficult and
requiresmultidisciplinary coordination. Studies such as thephase I
dose escalation study examining plasma pharmacokinetics and
cerebrospinal fluid concentration oferlotinib in patientswith high-
grade gliomas [19] and the recently published work by Morikawa
et al. on the penetrance of lapatinib and capecitabine into breast
cancer brain metastases when given preoperatively [20] could be
designed and implemented seamlessly in adedicatedBCBMclinic.
Historically, survival time after a diagnosis of BCBMwas 2 to
16 months [2, 5]. Evidence from our clinic and recent studies
suggests that this survival is nowmore than14months to2years
from CNS metastatic diagnosis [21, 22], including a median
survival of approximately 18 months to 3 years for HER21
disease[22].This improvementmaybeduetonewertherapeutic
strategies andbetter supportive care, but also argues for a focus
on coordinated and specialized care including neurosurgical,
radiation oncology, and medical oncology disciplines dedicated
to prolonging survival while maintaining optimal quality of life.
Although intriguing, this report of the initial experience in this
clinic has several limitations. First, we evaluated a relatively small
cohortof65patients seenoveraperiodof3years,which inherently
limits conclusions that can be drawn from the results. Second, to
date, we have only evaluated BCBM using this model; however,
we believe that this template could also be applicable to other
institutions interested in developing brain tumor clinics to treat
other solid tumor histologies (e.g., lung cancer, melanoma). Finally,
thereferralinformationforsupportiveservicessuchaspalliativecare
and the comprehensive cancer support program were difficult to
track,becausemany referralsweremadeverbally andnotcaptured
inthemedicalrecord,andsowecannotprovideaccuratedataonthe
percentage of patients who benefited from these programs. As a
future direction, we are actively designing a prospective pilot study
collectingsymptomburdenandqualityof lifeforpatientsseeninthe
BCBM clinic. We believe this valuable information will lead to
targeted interventions to best address the needs of our patients.
CONCLUSION
In summary, the UNC-CH Breast Cancer Brain Metastases Clinic
has been successful at providing vital multidisciplinary care for a
patient population facing a challenging diagnosis. In addition, this
model has provided a cohesive clinical paradigm for the spectrum
ofprovidersinvolvedinBCBMclinicalcareandresearch.Asweturn
Figure 1. Overall survival after diagnosis of brain metastases in all patients (A) and by subtype (B).
Abbreviations: CI, confidence interval; HR1, hormone receptor-positive; HER21, human epidermal growth receptor 2-positive; OS,
overall survival; TNBC, triple negative breast cancer.
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towardthefuture,weenvisionexpandingthescopeofourservices
by adding a pharmacist to the team, improving coordinationwith
our cancer support program so that wemay understand how our
patients benefit from available supportive services at UNC-CH,
increasing our trial portfolio to include studies focused on tissue-
based research, andexpandingour specialized services topatients
with brain metastases arising from other solid tumor types (e.g.,
melanoma, lung cancer) to reach a wider patient population.We
believe that our experience with a dedicated, multidisciplinary
clinic to treat patients with breast cancer brain metastases
has been successful in providing our patients with the most
comprehensive care including medical oncology, radiation oncol-
ogy, and neurosurgical services in an efficient and coordinated
manner. We hope that this description of the development and
logisticsofourclinicwill beuseful toother institutionswhomaybe
interested in undertaking a similar endeavor to provide such care
to patients with BCBM and other solid-tumor CNSmetastases.
ACKNOWLEDGMENTS
We acknowledge our UNC Medical Oncology team (Hy Muss,
Frances Collichio, Tim Brotherton, and Trevor Jolly) as well as
Larry Marks, Shelley Earp, and Patricia Saponaro. Research
reported in this publication was supported by the National
Cancer Instituteof theNational InstitutesofHealthunderaward
numberK23CA157728.Thecontent issolely theresponsibilityof
theauthorsanddoesnotnecessarily represent theofficial views
of the National Institutes of Health. Carey K. Anders is a Damon
Runyon Clinical Investigator supported in part by the Damon
Runyon Cancer Research Foundation (CI-64-12). Further
financial support was provided via Breast SPORE Career
Development funding 2-P50-CA058223-20 for Carey K. Anders,
and database support was provided in part through Komen
Foundation Grant SAC110044 for E. Claire Dees.
AUTHOR CONTRIBUTIONS
Conception/Design: Megan J. McKee, Amy L. Garrett, Matthew G. Ewend,
Carey K. Anders, Timothy M. Zagar
Provision of studymaterial or patients:Megan J.McKee, E. ClaireDees, Lisa A.
Carey, Matthew G. Ewend, Carey K. Anders, Timothy M. Zagar
Collection and/or assembly of data: Megan J. McKee, Kevin Keith, Allison M.
Deal, Amy L. Garrett, Amy A. Wheless, Rebecca L. Green, Julie M. Benbow,
Carey K. Anders, Timothy M. Zagar
Dataanalysis and interpretation:Megan J.McKee, KevinKeith,AllisonM.Deal,
Amy L. Garrett, Julie M. Benbow, E. Claire Dees, Lisa A. Carey, Matthew G.
Ewend, Carey K. Anders, Timothy M. Zagar
Manuscriptwriting:Megan J.McKee, Kevin Keith, AllisonM.Deal, LisaA.Carey,
Matthew G. Ewend, Carey K. Anders, Timothy M. Zagar
Final approval of manuscript: Megan J. McKee, Kevin Keith, Allison M. Deal,
Amy L. Garrett, AmyA.Wheless, Rebecca L. Green, JulieM. Benbow, E. Claire
Dees, Lisa A. Carey, Matthew G. Ewend, Carey K. Anders, Timothy M. Zagar
DISCLOSURES
E. Claire Dees: Novartis, Pfizer, Merck, Eli Lilly, Cerulean, Bayer (RF);
Carey K. Anders: Novartis, Sanofi, BBB Therapeutics, Geron, AngioChem,
Merrimack, Eli Lilly, Genentech (C/A), Novartis, Sanofi, BBB Therapeutics,
AngioChem,Merrimack, Bristol-Myers Squibb, Eli Lilly, and Puma (RF).
The other authors indicated no financial relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert
testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/
inventor/patent holder; (SAB) Scientific advisory board
REFERENCES
1. Kirsch DG, Loeffler JS. Brain metastases in
patients with breast cancer: New horizons. Clin
Breast Cancer 2005;6:115–124.
2. Boogerd W, Vos VW, Hart AA et al. Brain
metastases inbreastcancer;naturalhistory,prognostic
factors and outcome. J Neurooncol 1993;15:165–174.
3. Bendell JC, Domchek SM, Burstein HJ et al.
Central nervous system metastases in women who
receive trastuzumab-based therapy for metastatic
breast carcinoma. Cancer 2003;97:2972–2977.
4. Lin NU, Claus E, Sohl J et al. Sites of distant
recurrence and clinical outcomes in patients with
metastatic triple-negative breast cancer: High in-
cidence of central nervous system metastases.
Cancer 2008;113:2638–2645.
5.Weil RJ, Palmieri DC, Bronder JL et al. Breast
cancermetastasis to thecentralnervous system.Am
J Pathol 2005;167:913–920.
6. DawoodS, Broglio K, Esteva FJ et al. Survival among
women with triple receptor-negative breast cancer
and brainmetastases. Ann Oncol 2009;20:621–627.
7. Niwin´ska A, Murawska M, Pogoda K. Breast
cancer brain metastases: Differences in survival
depending on biological subtype, RPA RTOG prog-
nosticclassandsystemic treatmentafterwhole-brain
radiotherapy (WBRT). Ann Oncol 2010;21:942–948.
8. Bartsch R, Rottenfusser A, Wenzel C et al.
Trastuzumab prolongs overall survival in patients
with brain metastases from HER2 positive breast
cancer. J Neurooncol 2007;85:311–317.
9. OkitaY,NaritaY,SuzukiTetal.Extendedtrastuzumab
therapy improves the survival of HER2-positive breast
cancer patients following surgery and radiotherapy for
brainmetastases. Mol Clin Oncol 2013;1:995–1001.
10. Zhang Q, Chen J, Yu X et al. Survival benefit of
anti-HER2 therapy after whole-brain radiotherapy
in HER2-positive breast cancer patients with brain
metastasis. Breast Cancer 2015.
11. EwendMG,MorrisDE,Carey LAetal.Guidelines
for theinitialmanagementofmetastaticbraintumors:
role of surgery, radiosurgery, and radiation therapy. J
Natl Compr Canc Netw 2008;6:505–513; quiz 514.
12. Khuntia D, Brown P, Li J et al. Whole-brain
radiotherapy in the management of brain metasta-
sis. J Clin Oncol 2006;24:1295–1304.
13. Gaspar L, Scott C, Rotman M et al. Recursive
partitioning analysis (RPA) of prognostic factors in
three Radiation Therapy Oncology Group (RTOG)
brain metastases trials. Int J Radiat Oncol Biol Phys
1997;37:745–751.
14. Sperduto PW, Kased N, Roberge D et al. Effect
of tumor subtype on survival and the graded
prognostic assessment for patients with breast
cancer and brain metastases. Int J Radiat Oncol Biol
Phys 2012;82:2111–2117.
15. Linskey ME, Andrews DW, Asher AL et al. The
roleof stereotactic radiosurgery in themanagement
of patients with newly diagnosed brain metastases:
A systematic review and evidence-based clinical
practice guideline. J Neurooncol 2010;96:45–68.
16. Kelly PJ, Lin NU, Claus EB et al. Salvage
stereotactic radiosurgery for breast cancer brain
metastases: Outcomes and prognostic factors.
Cancer 2012;118:2014–2020.
17. Chang EL, Wefel JS, Hess KR et al. Neuro-
cognition in patients with brain metastases treated
with radiosurgery or radiosurgery plus whole-brain
irradiation: A randomised controlled trial. Lancet
Oncol 2009;10:1037–1044.
18. Danielson B, Fairchild A. Beyond palliative
radiotherapy: A pilot multidisciplinary brain metas-
tases clinic. Support Care Cancer 2012;20:773–781.
19. Buie LWLC, Shih T, Ewend M et al. . Plasma
pharmacokinetics and cerebrospinal fluid concentra-
tionsoferlotinib inhigh-gradegliomas:Anovel, phase I,
doseescalationstudy..JClinOncol 2007;;25:(18S):2054.
20.Morikawa A, Peereboom DM, Thorsheim HR
et al. Capecitabine and lapatinib uptake in surgically
resected brain metastases from metastatic breast
cancer patients: A prospective study. Neuro-oncol
2015;17:289–295.
21. Leone JP, Lee AV, Brufsky AM. Prognostic
factorsandsurvivalofpatientswithbrainmetastasis
from breast cancer who underwent craniotomy.
Cancer Med 2015;4:989–994.
22. Shen Q, Sahin AA, Hess KR et al. Breast cancer
with brain metastases: Clinicopathologic features,
survival, andpairedbiomarkeranalysis.TheOncologist
2015;20:466–473.
CME This article is available for continuing medical education credit at CME.TheOncologist.com.
©AlphaMed Press 2016
TheOncologist®
20 UNC’s Breast Cancer Brain Metastases Clinic
CM
E
